Supplement use of drug brand names to be addressed in commission report response.
This article was originally published in The Tan Sheet
Executive Summary
SUPPLEMENT NAMES BASED ON DRUG PRODUCTS WILL BE ADDRESSED in FDA's pending response to the report of the President's Commission on Dietary Supplement labels, according to FDA Division of Drug Labeling and OTC Compliance Director Bradford Williams. The agency's response to the commission's report has been under review at the Office of Management & Budget and is expected to be published soon in the Federal Register. Williams spoke at the Nonprescription Drug Manufacturers Association small business/marketing seminar in East Rutherford, N.J. March 11-12.